Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. (Q34516049)

2 August 2017

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. (English)

1 reference

2 August 2017

phase I clinical trial

0 references

author

Christophe Le Tourneau

1

object named as

Christophe Le Tourneau

0 references

author name string

Hui K Gan

2

1 reference

2 August 2017

Albiruni R A Razak

3

1 reference

2 August 2017

Xavier Paoletti

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

12 December 2012

1 reference

2 August 2017

1 reference

2 August 2017

7

1 reference

2 August 2017

12

1 reference

2 August 2017

e51039

1 reference

Creative Commons Attribution 4.0 International

2 August 2017

start time

12 December 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521009

Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521009

Dose escalation methods in phase I cancer clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521009

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3521009

Translation of innovative designs into phase I trials.

7 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051039

Dose-finding based on efficacy-toxicity trade-offs

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051039

An adaptive dose-finding design incorporating both toxicity and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051039

Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051039

Continual reassessment method for ordered groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0051039

Sequential designs for phase I clinical trials with late-onset toxicities

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23251419

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Dose escalation trial designs based on a molecularly targeted endpoint

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23251419

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23251419

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0051039

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference